-
公开(公告)号:US20110189669A1
公开(公告)日:2011-08-04
申请号:US13000079
申请日:2009-06-19
申请人: Laki Buluwela , Jonathan Waxman , Simak Ali , Sarah Ngan
发明人: Laki Buluwela , Jonathan Waxman , Simak Ali , Sarah Ngan
CPC分类号: G01N33/57434 , A61K31/00 , A61K31/167 , A61K31/519 , A61K31/7076 , A61K31/7088 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/154 , C12Q2600/158 , G01N2333/91017 , A61K2300/00
摘要: The current invention provides a method for aiding in the assessment of prostate cancer (including metastatic prostate cancer) and/or benign prostate hyperplasia in a patient, wherein the method comprises the step of determining the level of Glycine N-methyltransferase (GNMT) nucleic acid and/or protein in a sample from the patient. The invention also provides compounds that target Glycine N-methyltransferase (GNMT) protein and/or nucleic acid for use in treating prostate cancer. Also provided are screening methods for selecting a compound considered to be useful in treating prostate cancer, comprising the steps of determining the ability of a test compound to reduce GNMT activity and selecting a compound that reduces GNMT activity. The invention also provides methods for aiding in the diagnosis of prostate cancer in a patient comprising obtaining a sample from the patient and assessing said sample for a marker of GNMT activity.
摘要翻译: 本发明提供了一种帮助评估患者前列腺癌(包括转移性前列腺癌)和/或良性前列腺增生的方法,其中该方法包括确定甘氨酸N-甲基转移酶(GNMT)核酸水平的步骤 和/或来自患者的样品中的蛋白质。 本发明还提供靶向用于治疗前列腺癌的甘氨酸N-甲基转移酶(GNMT)蛋白和/或核酸的化合物。 还提供了用于选择被认为可用于治疗前列腺癌的化合物的筛选方法,包括确定测试化合物降低GNMT活性并选择降低GNMT活性的化合物的能力的步骤。 本发明还提供了帮助诊断患者中前列腺癌的方法,包括从患者获得样品并评估所述样品以获得GNMT活性标志物。